Aura Biosciences, Inc.

NASDAQ:AURA

Biotechnology

Healthcare
$7.14 -1.43%

-$0.09 today

Market cap
$743.09M
Beta
0.39
P/E (TTM)
-3.7
EPS (TTM)
-$1.67
52W Low $4.73High $9.54

Volume 0.69M

Average 0.52M

AURA Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Aura Biosciences, Inc.NASDAQ: AURA

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses growth accelerates

Q1 FY2026 operating expenses of $34.59M rose 19.1% year over year, ahead of the +15.1% change in trailing-twelve-month operating expenses. Sequentially, it rose 27.0% from the prior quarter. Over 3 fiscal years it compounded at +23.2% a year.

Context

  • Operating expenses increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +19.1% holds above the trailing-twelve-month pace of +15.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$34.59M+27.0% QoQ
Last fiscal yearDec 2025
$112.79M+17.3% YoY
LTMMar 2026
$118.05M+15.1% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+19.1%——
1 year+17.3%——
3-year CAGR+23.2%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
112.79M USD
Year-over-year change
+17.3%
4-year CAGR
+33.7%

Operating Expenses vs competitors

How AURA compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +15.1% is the 7th highest of 11, against a peer median of +43.1%.
  • Over three fiscal years its annual growth of +23.2% compares with a peer median of +34.7%.
AURA Competitors
Operating Expenses for AURA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMNMImmunome, Inc.LTM Sep 2026$299.94M USD+54.6%+80.8%—
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$287.65M USD+34.6%+27.1%3777.4%
BCYCBicycle Therapeutics plcLTM Mar 2026$234.87M USD+104.1%+34.7%369.9%
MGNXMacroGenics, Inc.LTM Mar 2026$173.51M USD-10.6%-12.1%110.5%
WHWKWhitehawk Therapeutics IncLTM Mar 2026$122.7M USD+143.6%+40.1%—
AURAAura Biosciences, Inc.LTM Mar 2026$118.05M USD+15.1%+23.2%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$89.69M USD+109.1%+36.8%—
AKTSAktis Oncology, Inc.FY2025$81.18M USD+51.6%+60.1%1249.5%
OCGNOcugen, Inc.LTM Mar 2026$70.72M USD+14.9%-10.8%1583.9%
OCSOculis Holding AGLTM Mar 2026CHF 69.81M CHF-10.3%+34.7%13851.6%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$59.37M USD-22.3%+2.5%17821.9%
Peer median (excluding AURA) —+43.1%+34.7%1583.9%

Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue001.3M00
Gross Profit00(1.3M)00
Gross Margin—————
Research & Development25.16M42.24M63.94M73.3M90.3M
Selling, General & Admin10.09M18.06M19.76M22.81M22.49M
Operating Expenses35.25M60.3M83.7M96.12M112.79M
Depreciation & Amortization831K1.18M1.3M1.22M1.13M
EBITDA(34.41M)(57.59M)(74.98M)(85.58M)(104.95M)
EBITDA Margin—————
Operating Income(35.25M)(60.3M)(84.99M)(96.12M)(112.79M)
Operating Margin—————
Interest Income13K1.86M8.59M9.43M6.63M
Interest Expense13K0000
Other Income / Expenses(1K)1.53M8.72M9.31M6.71M
Income Before Tax(35.25M)(58.76M)(76.27M)(86.81M)(106.08M)
Pre-Tax Margin—————
Income Tax Expense00137K112K108K
Net Income(35.25M)(58.76M)(76.41M)(86.92M)(106.19M)
Net Margin—————
EPS (Basic)(1.58)(1.96)(1.93)(1.75)(1.76)
EPS (Diluted)(1.58)(1.96)(1.93)(1.75)(1.76)
Weighted Avg Shares29.21M29.94M39.62M49.65M60.34M
Weighted Avg Shares (Diluted)29.21M29.94M39.62M49.65M60.34M

Aura Biosciences, Inc.

NASDAQ:AURA

Intrinsic Alpha fair value

Locked

Current Price

$7.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.